At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
AR101 powder provided in capsules +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy
In Brief
A Phase 2 clinical trial evaluating AR101 powder provided in capsules and Placebo powder provided in capsules for Peanut Allergy. Completed, enrolled 56 participants across 8 sites.
Detailed Summary
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartFeb 2014
Primary CompletionJan 2015
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartFeb 6, 2014
Primary CompletionJan 7, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.6 years ago
Interventions
AR101 powder provided in capsulesbiological
Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Placebo powder provided in capsulesbiological
Study product formulated to contain only inactive ingredients for use as defined in the protocol